Integrated care model and point of care diagnostics facilitate Hepatitis C treatment among patients receiving opioid agonist therapy : a retrospective review of medical records

Show full item record



Permalink

http://hdl.handle.net/10138/345989

Citation

Häkkinen , M , Tourunen , J , Pitkänen , T , Simojoki , K & Vuoti , S 2022 , ' Integrated care model and point of care diagnostics facilitate Hepatitis C treatment among patients receiving opioid agonist therapy : a retrospective review of medical records ' , Substance abuse treatment, prevention and policy , vol. 17 , no. 1 , 44 . https://doi.org/10.1186/s13011-022-00473-3

Title: Integrated care model and point of care diagnostics facilitate Hepatitis C treatment among patients receiving opioid agonist therapy : a retrospective review of medical records
Author: Häkkinen, Margareeta; Tourunen, Jouni; Pitkänen, Tuuli; Simojoki, Kaarlo; Vuoti, Sauli
Contributor organization: Department of Psychiatry
University of Helsinki
HUS Psychiatry
Date: 2022-06-02
Language: eng
Number of pages: 10
Belongs to series: Substance abuse treatment, prevention and policy
ISSN: 1747-597X
DOI: https://doi.org/10.1186/s13011-022-00473-3
URI: http://hdl.handle.net/10138/345989
Abstract: Background Hepatitis C virus (HCV) is common among individuals in opioid agonist therapy (OAT). HCV treatment has previously been unavailable for most HCV positive OAT patients in Finland. The removal of treatment restrictions and attempts to reach HCV elimination goals have increased the number of OAT patients needing HCV treatment. The objectives of this study were 1) to characterize Finnish HCV positive OAT patients and evaluate their eligibility for HCV treatment at addiction service units, and 2) to retrospectively review the outcomes of treated patients. Methods The study focused on HCV positive OAT patients (n = 235). Demographics and clinical parameters were retrospectively reviewed using the patients' medical records. The eligibility of providing HCV treatment to patients at addiction service units were evaluated based on patients' clinical characteristics, such as liver function and patterns of substance use. The outcomes of patients receiving HCV treatment were reviewed. Results Of HCV antibody positive OAT patients, 75% had chronic HCV. Of 103 HCV patients screened for liver fibrosis either with Fibroscan or APRI (aspartate aminotransferase to platelet ratio index), 83 patients (81%) had no indication of severe liver damage. Point of care (POC) HCV tests were used for 46 patients to lower the threshold of attending laboratory testing. All patients preferred POC testing to conventional blood testing. Twenty patients had received HCV treatment, 19 completed the treatment and achieved sustained virologic response (SVR) at the end of the treatment. Of the 18 patients available for evaluation of SVR at 12 weeks after the treatment (SVR12), 17 achieved SVR12. Conclusions The integrated model consisting of HCV diagnostics and treatment at the addiction service unit was successfully implemented within normal OAT practice.
Subject: Hepatitis C
People who inject drugs
Opioid agonist therapy
Linkage to care
Point of care diagnostics
INJECT DRUGS
PEOPLE
VIRUS
KNOWLEDGE
3124 Neurology and psychiatry
Peer reviewed: Yes
Rights: cc_by
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
Integrated_care_model_and_point_of_care...pdf 2.823Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record